Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 Dose-Finding Study in Overweight or Obesity
NCT06326060Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 3
01
Overview
A Phase 2 trial of NNC0519-0130 in obesity, sponsored by Novo Nordisk. Started Mar 2024; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06326060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326060.